Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Autor: Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes

Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)

Abstract Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and b

Externí odkaz: https://doaj.org/article/3f6add655fbe4b0d92de37dd9a97fca3

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

Autor: Ivana Zagorac, Sara Fernandez-Gaitero, Renske Penning, Harm Post, Maria J. Bueno, Silvana Mouron, Luis Manso, Manuel M. Morente, Soledad Alonso, Violeta Serra, Javier Muñoz, Gonzalo Gómez-López, Jose Francisco Lopez-Acosta, Veronica Jimenez-Renard, Albert Gris-Oliver, Fatima Al-Shahrour, Elena Piñeiro-Yañez, Jose Luis Montoya-Suarez, Juan V. Apala, Amalia Moreno-Torres, Ramon Colomer, Ana Dopazo, Albert J. R. Heck, Maarten Altelaar, Miguel Quintela-Fandino

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)

Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, the authors use phosphoproteomics to define kinases with distinct activity profiles in TNBC, demonstrating their prognostic value as well as their utility for simplif

Externí odkaz: https://doaj.org/article/6508e17c6fdd4f1a8cecab535185385a

Figure S1 from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Autor: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

Supplementary Figure 1: Microvessel confocal staining broken down by fluorescence channel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a157e7aab0fba6805e9a15ee8e9edbe
https://doi.org/10.1158/1078-0432.22475901

Data from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Autor: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

Purpose:We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3f985d5e8e7524e5de28637a2d268
https://doi.org/10.1158/1078-0432.c.6529209.v1

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Autor: Esther Holgado, Orlando Dominguez, Juan V. Apala, Javier Cortes, Diego Malón, Santos Mañes, Luis Manso, Serafin Morales, Silvana Mouron, Antonio Lopez-Alonso, M. I. Martínez, Ramon Colomer, Javier Hornedo, Raquel Blanco, Ariadna Gasol Cudós, Begoña Bermejo, Lucía González-Cortijo, Vega Iranzo, Manuel Muñoz, María del Carmen Moreno-Ortiz, Eduardo Caleiras, Miguel Quintela-Fandino

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repisalud
Instituto de Salud Carlos III (ISCIII)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
BREAST CANCER RESEARCH
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Breast Cancer Research : BCR
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)
Scientia

© The Author(s).
[Background]: Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842a246ba615e772839387f7783c0eec
https://hdl.handle.net/20.500.12530/54354